04. June 2015

    "Biotherapeutic Immunomodulation as a Countermeasure to  Hyperinflammatory Tissue Damage - A Double-Blind, Phase 1 Human Study of Osteoarthritis, with Surprisin

    Presentation and Research Paper presented at the PharmaLunch May, 2015 of the Swiss Academy of Pharmaceutical Sciences in Basel, Switzerland 

    Steven Taub, Research and Development Manager, Cardiovascular Surgery Department, Centre Hospitalier Universitaire Vaudois, CHUV,  Lausanne

    More information and downloads

    Tags: excipient, SAPhW, jun2015, PharmaLunch, Taub, CHUV, Biotherapeutic, Agent, Osteoarthritis, Heme, oxygenase-1, Sour, cherry, Cytokines, Inflammation